Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma

How cancer cells evade the therapeutic effects of immune checkpoint blockade is largely unknown. Here, we report that fibrinogen-like protein 1 (FGL1), a newly identified immune checkpoint ligand, was modified by acetylation at Lys 98 in hepatocellular carcinoma (HCC), which targeted it for proteaso...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Mingen, He, Jing, Zhang, Xinchao, Sun, Xue, Dong, Wenjing, Zhang, Ruonan, Xu, Yanping, Lv, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145938/
https://www.ncbi.nlm.nih.gov/pubmed/37115693
http://dx.doi.org/10.1172/JCI164528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145938/
https://www.ncbi.nlm.nih.gov/pubmed/37115693
http://dx.doi.org/10.1172/JCI164528

Ejemplares similares